New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
08:42 EDTIG, MNKMallinckrodt grants IGI Labs non-exclusive license to launch generic PENNSAID
IGI Laboratories (IG) announced that it has entered into an agreement with Mallinckrodt (MNK) and Nuvo Research to settle a declaratory judgment action brought by IGI, concerning IGI's filing of an abbreviated new drug application with the FDA seeking approval to market a generic version of PENNSAID 1.5% w/w. Under the terms of this agreement, Mallinckrodt granted IGI a non-exclusive license to launch its diclofenac sodium topical solution 1.5% product on March 28, 2015. IGI received tentative approval of its diclofenac sodium topical solution 1.5% from the FDA on May 7. IGI CEO Jason Grenfell-Gardner said, "The agreement provides IGI with a date certain launch of diclofenac sodium topical solution 1.5%. We remain confident in our ability to obtain final FDA approval of our ANDA for diclofenac sodium topical solution 1.5% prior to our agreed upon launch date. The agreement allows IGI to continue to expand its portfolio of generic topical prescription drug products."
News For IG;MNK From The Last 14 Days
Check below for free stories on IG;MNK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
09:21 EDTMNKMallinckrodt now a component of the S&P 500 Index
The inclusion comes following the completion of Mallinckrodt’s acquisition of Questcor Pharmaceuticals last week. In addition to increasing the market capitalization of Mallinckrodt, the combination has significantly strengthened the company’s balance sheet, cash generation and leverage position.
August 14, 2014
17:20 EDTMNKRowan Companies to replace Mallinckrodt in S&P 400 as of 8/18 close
Subscribe for More Information
17:18 EDTMNKMallinckrodt to replace Rowan Companies in S&P 500 as of 8/18 close
17:16 EDTMNKPaulson & Co gives quarterly update on stakes
Subscribe for More Information
16:35 EDTMNKMallinckrodt completes acquisition of Questcor Pharmaceuticals
Subscribe for More Information
13:02 EDTMNKMallinckrodt, Questcor holders approve Mallinckrodt's acquisition of Questcor
Subscribe for More Information
12:58 EDTMNKJANA Partners gives quarterly update on stakes
NEW STAKES: Apache (APA), FMC Corp (FMC), Civeo (CVEO), PetSmart (PETM), and Charter Communications (CHTR). INCREASED STAKES: Actavis (ACT), AIG (AIG), Mallinckrodt (MNK), HD Supply (HDS), and American Capital (ACAS). DECREASED STAKES: Liberty (LVNTA), Oil States International (OIS), eBay (EBAY), Liberty Media (LMCA), and Liberty Interactive (LINTA). LIQUIDATED STAKES: Sirius XM (SIRI), Juniper (JNPR), Golar LNG (GLNG), Outerwall (OUTR), and Teva (TEVA).
August 8, 2014
08:31 EDTMNKMallinckrodt patent settlement removes key overhang, says Deutsche Bank
Subscribe for More Information
07:45 EDTMNKMallinckrodt price target lowered to $77 from $90 at Leerink
Leerink lowered its price target for Mallinckrodt (MNK) shares to $77 citing a heightened risk profile from the Questcor (QCOR) acquisition and significant earnings concentration in Acthar. The firm says it remains on the sidelines with a Market Perform rating on Mallinckrodt.
07:44 EDTMNKMallinckrodt remains favorite specialty pharmaceutical name, says UBS
UBS said Mallinckrodt (MNK) remains its favorite specialty pharmaceutical name following the company's update on its merger with Questcor (QCOR). The firm sees estimates increasing following the close of the transaction, the divestiture of the Medical Imaging division, and the reinvestment in higher margin assets. UBS has a Buy rating with a $94 price target on Mallinckrodt.
August 7, 2014
07:05 EDTMNKMallinckrodt raises FY14 adjusted EPS view to $4.00-$4.30 from $3.30-$3.60
Consensus is $3.82. Raises FY14 net sales view to $2.35B-$2.45B from $2.28B-$2.38B, consensus $2.38B. Cuts FY CapEx view to $115M-$135M from $130M-$150M. Now sees tax rate 22%-25%.
07:03 EDTMNKMallinckrodt reports Q3 adjusted EPS $1.20, consensus 87c
Subscribe for More Information
August 6, 2014
17:46 EDTMNKMallinckrodt announces settlement of Ofirmev injection patent litigation
Subscribe for More Information
08:16 EDTMNKMallinckrodt receives patent from U.S. PTO
Mallinckrodt (MNK) announced that on July 29 the U.S. Patent and Trademark Office granted the company a new patent related to MNK-155. The patent, U.S. Patent Number 8,790,694 contains composition claims directed to unique design, formulation, pharmacokinetic, and release characteristics of MNK-155 and conveys the same period of exclusivity as did the patent granted in 2013 for the company’s product XARTEMIS XR Extended-Release Tablets. MNK-155 is Mallinckrodt’s investigational extended-release oral formulation of hydrocodone and acetaminophen studied for the management of moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate. The release profile of MNK-155 combines Mallinckrodt-proprietary technology and Depomed’s (DEPO) advanced Acuform drug delivery technology.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use